Double-blind cross-over study of the effect of sultosilic acid piperazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia.
Sultosilic acid piperazine salt (A-585), a new lipid lowering drug, was compared with the action of bezafibrate. In 20 patients suffering from primary hyperlipoproteinemia a double-blind cross-over study was carried out. A series of parameters of the lipoprotein metabolism, as well as of fibrinolysis and platelet function, was compared before and after administration of the drugs. There was a statistically significant diminution of total cholesterol, triglycerides, beta- and pre-beta-cholesterol and an increase of alpha-cholesterol by both drugs. Furthermore, both drugs caused a significant shortening of the euglobulin lysis time and a significant diminution of platelet adhesiveness. In patients who were under oral anticoagulants the thrombotest levels were not influenced by A-585 but were frequently below the therapeutic range during bezafibrate therapy. The difference in the thrombotest during treatment with the 2 drugs was significant. A slightly elevated gamma-GT activity normalized during bezafibrate therapy but was not influenced by A-585. Other parameters did not show significant differences between the 2 drugs.
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use*; D001629:Bezafibrate / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D004347:Drug Interactions; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood; D008875:Middle Aged; D010973:Platelet Adhesiveness / Q000187:drug effects; D014280:Triglycerides / Q000097:blood
D000925:Anticoagulants; D001557:Benzenesulfonates; D008074:Lipoproteins; D014280:Triglycerides; C024325:sultosilic acid; D002784:Cholesterol; D001629:Bezafibrate